Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients

AIDS

Volumn 26, Issue 3, 2012, Pages 253-262

  Childs, Kathryn ^a   Welz, Tanya ^a   Samarawickrama, Amanda ^b   Post, Frank A ^a,c  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antiretroviral therapy; bone mineral density; bone turnover; fractures; HIV; parathyroid hormone; vitamin D

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM CARBONATE; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PARATHYROID HORMONE; RILPIVIRINE; RITONAVIR; TENOFOVIR; VITAMIN D; ZIDOVUDINE;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL (TOPIC); DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MEDLINE; MONOTHERAPY; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; SYSTEMATIC REVIEW; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANTI-HIV AGENTS; BONE DENSITY; DRUG THERAPY, COMBINATION; FEMALE; FRACTURES, BONE; HIV SEROPOSITIVITY; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84855354913     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834f324b     Document Type: Review

References (79)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio AM, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29. (Pubitemid 36835816)
2. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671. (Pubitemid 34921112)
3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174. (Pubitemid 44684707)
4. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923-1928.
5. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitaminDLevels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405.
6. Adeyemi OM, Agniel D, French AL, Tien P, Weber K, Glesby MJ, et al. Vitamin D deficiency in HIV-infected and un-infected women in the US. J Acquir Immune Defic Syndr 2011; 57:197-204.
7. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
8. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
9. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-1930.
10. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
11. Ormesher B, Dhaliwal S, Nylen E, Gibert C, Go C, Amdur R, et al. Vitamin Ddeficiency is less common among HIV-infected African-American men than in a matched cohort. AIDS 2011; 25:1237-1239.
12. Stein EM, Yin MT, McMahon DJ, Shu A, Zhang CA, Ferris DC, et al. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int 2011; 22:477-487.
13. Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006; 25:537-539. (Pubitemid 44137629)
14. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr 2006; 83:1135-1141. (Pubitemid 44713115)
15. Harris SS, Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 1998; 67:1232-1236. (Pubitemid 28259512)
16. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010; 24:1127-1134.
17. Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 2010; 54:496-499.
18. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011; 25:1305-1315.
19. Kim JH, Gandhi V, Psevdos G, Espinoza F, Park J, Sharp V. Evaluation of Vitamin D Levels among HIV-Infected Patients in New York City. AIDS Res Hum Retroviruses 2011 (Epub ahead of print).
20. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1375-1382.
21. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses 2009; 25:9-14.
22. Pasquet A, Viget N, Ajana F, de la Tribonniere X, Dubus S, Paccou J, et al. Vitamin D deficiency in HIV infected patients: associated with NNRTI or efavirenz use? AIDS 2011; 25:873-874.
23. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010; 15:425-429.
24. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther 2010; 7:40.
25. Lattuada E, Lanzafame M, Zoppini G, Concia E, Vento S. No influence of nevirapine on vitamin D deficiency in HIVinfected patients. AIDS Res Hum Retroviruses 2009; 25:849-850.
26. Fux CA, Baumann S, Furrer H, Mueller NJ. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the nonnucleoside reverse transcriptase inhibitor class? AIDS 2011; 25:876-878.
27. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. AIDS Res Hum Retroviruses 2011; 27:29-34.
28. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23:1367-1376.
29. Rockstroh J, Stoehr A, Duiculescu D, Voronin E, Hill A, van Delft Y, et al. Analysis of vitaminDand parathyroid hormone in the SENSE trial: etravirine versus efavirenz in treatment-naive HIV-1 infected patients. Antiviral Therapy 2010; 15:A42-43.
30. Wohl D, Doroana M, Orkin C, Pilotto JH, Sungkanuparph S, Yeni P, et al. Change in vitamin D levels smaller and risk of development of severe vitaminDdeficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-Week results from the Phase III ECHO Trial [abstract 79LB]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011; Boston. MA, USA.
31. Welz T, Childs K, Post FA. Do nevirapine and efavirenz affect vitamin D homeostasis similarly? AIDS 2011; 25:875-876.
32. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009; 75:1392-1399.
33. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2+1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004; 101:7711-7715. (Pubitemid 38658094)
34. Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115:177-186. (Pubitemid 40385519)
35. Landriscina M, Altamura SA, Roca L, Gigante M, Piscazzi A, Cavalcanti E, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer 2008; 122:2842-2850. (Pubitemid 351631388)
36. Ramayo E, Gonzalez-Moreno MP, Macias J, Cruz-Ruiz M, Mira JA, Villar-Rueda AM, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2005; 21:915-921. (Pubitemid 41785776)
37. Daria P, Laura C, Elena R, Davide M, Monica S, Paola M, et al. Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy? AIDS 2011; 25:1430-1433.
38. Childs KE, Fishman SL, Constable C, Gutierrez JA, Wyatt CM, Dieterich DT, et al. Short communication: inadequate vitamin d exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 2010; 26:855-859.
39. Masia M, Padilla S, Robledano C, Lopez N, Ramos JM, Gutierrez F. Early Changes in Parathyroid Hormone Concentrations in HIV-Infected Patients Initiating Antiretroviral Therapy with Tenofovir. AIDS Res Hum Retroviruses 2011 (Epub ahead of print).
40. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23:689-696.
41. Bang UC, Shakar SA, Hitz MF, Jespersen MS, Andersen O, Nielsen SD, et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis 2010; 42:306-310.
42. Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010; 53:202-208.
43. Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008; 13:1077-1082.
44. Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591-1601.
45. Piso RJ, Rothen M, Rothen JP, Stahl M. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr 2011; 56:320-324.
46. Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004; 48:39-48. (Pubitemid 39069663)
47. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200:1746-1754.
48. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17:1917-1923. (Pubitemid 37070277)
49. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51:963-972.
50. Van Vonderen M, Mallon P, Murray B, Doran P, Van Agtmael M, Danner S, et al. Changes in bone biomarkers in ARV-naive HIVR men randomized to NVP/LPV/r or AZT/3TC/LPV/r help explain limited loss of bone mineral density over the first 12 months after ART initiation [abstract 833]. 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011, Boston. MA, USA.
51. Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis 2010; 23:1-8.
52. Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005; 16:1345-1352. (Pubitemid 41534646)
53. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006; 91:2938-2945. (Pubitemid 44271739)
54. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008; 49:298-308.
55. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24:2827-2833.
56. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
57. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviralnaive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
58. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23:817-824.
59. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 2011; 12:157-165.
60. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201. (Pubitemid 38917996)
61. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-561.
62. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIVinfected patients. J Acquir Immune Defic Syndr 2011; 57:205-210.
63. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009; 23:1021-1024.
64. Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24:2679-2686.
65. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007; 18:1345-1353. (Pubitemid 47389474)
66. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6:e17217.
67. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21:617-623.
68. Bedimo R, Zhang S, Drechsler H, Tebas P, Maalouf N. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents [abstract MOAB01]. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 17-20 July 2011; Rome, Italy.
69. Childs K, Kadish C, Branch-Elliman W, Fishman S, Mullen M, Branch A. Vitamin D and calcium supplements reverse the secondary hyperparathyroidism that commonly occurs. HIV Medicine 2009; 10 (Suppl. 1):36-37.
70. van den Bout-van den Beukel CJ, van den Bos M, Oyen WJ, Hermus AR, Sweep FC, Tack CJ, et al. The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med 2008; 9:771-779.
71. Havens P, Hazra R, Stephensen C, van Loan M, Rutledge B, Bethel J, et al. Vitamin D3 Supplementation Decreases PTH in HIV infected Youth Being Treated with TDF-containing Combination ART: A Randomized, Double-blind, Placebo-controlled Multicenter Trial: Adolescent Trials Network Study 063 [abstract 80]. 18thConference on Retroviruses and Opportunistic Infections;27 February-2 March 2011; Boston. MA, USA.
72. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38:426-431. (Pubitemid 40381552)
73. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21:2473-2482. (Pubitemid 350145179)
74. Prevention and management of noninfectious co-morbidities in HIV. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/ eacsguidelines-6.pdf. [Accessed 12 October 2011].
75. Post F, McCloskey E, Compston J, Bowman C, Hay P, Johnson M, et al. Prevention of bone loss and management of fracture risk in HIV-infected individuals: case studies and recommendations for different patient subgroups. Future Virol 2011; 6:769-782.
76. FRAX. WHO fracture risk assessment tool. http://www.shef.ac.uk/FRAX/ index.jsp. [Accessed 6 October 2011].
77. Avenell A, Gillespie WJ, Gillespie LD, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis. Cochrane Database Syst Rev 2009:CD000227.
78. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 2010; 5:e8770.
79. Mehta S, Hunter DJ, Mugusi FM, Spiegelman D, Manji KP, Giovannucci EL, et al. Perinatal outcomes, including motherto-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J Infect Dis 2009; 200:1022-1030.